Merck's Innovative Cancer Treatment Data to be Revealed at ASH 2025.

RAHWAY, N.J., November 24, 2025 – Merck (NYSE: MRK), known as MSD outside of the United States, announced that it will present new data on various hematologic malignancies at the American Society of Hematology (ASH) Annual Meeting, taking place December 6-9 in Orlando, Florida. The data presented at the meeting will highlight Merck's commitment to a broad and diverse set of clinical research initiatives, with over 20 abstracts to be shared.

Dr. Gregory Lubiniecki, Vice President of Global Clinical Development at Merck Research Laboratories, said, “The data we will share at ASH 2025 reflects the growth and evolution of our hematology pipeline. We are advancing a diverse portfolio aimed at addressing critical needs in hematologic neoplasms and malignancies while maintaining our leadership in oncology.”

Among the presentations from Merck will be MK-1045; an investigational CD19xCD3 T-cell engager, bomedemstat (MK-3543); an orally administered lysine-specific demethylase 1 (LSD1) inhibitor, and nemtabrutinib (MK-1026); an investigational reversible Bruton's tyrosine kinase (BTK) inhibitor. Additionally, zilovertamab vedotin (MK-2140); an antibody-drug conjugate targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1), will be presented with new and updated results.

Key data from Merck to be presented at the ASH 2025 Annual Meeting:

• Updated results from the Phase 1b/2 study evaluating the efficacy and safety of MK-1045 in adults with relapsed or refractory B-cell acute lymphoblastic leukemia (Abstract #647).
• First results of the Phase 2 Shorespan-004 study evaluating the efficacy of bomedemstat in patients with polycythemia vera (PV) (Abstract #83).
• Initial findings from an analysis of resistance gained and prognostic mutations in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) treated with nemtabrutinib (Abstract #797).

Merck’s commitment to maintaining its leadership in hematology aims to enhance the quality of life for patients through innovative approaches in cancer treatment. The company seeks to revolutionize the treatment of various hematologic neoplasms and malignancies with both monotherapy and combination therapies.